azithromycin plus hydroxychloroquine for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
ProPAC-COVID NCT04322396		RCT	azithromycin plus hydroxychloroquine	placebo	COVID 19 hospitalized	low	61/56	inconclusive
COVID-19 mild to moderate meta-analysis
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI NCT04322123		RCT	azithromycin plus hydroxychloroquine	standard of care	COVID-19 mild to moderate	some concern	217/227	safety concern	inconclusive 1 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias statistically significant 1.2-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias statistically significant 2.5-fold increase in elevated liver enzymes with a moderate degree of certainty due to some concern in risk of bias statistically significant 8.8-fold increase in long QT with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis